Search Filters

Search Results

Found 2 results

510(k) Data Aggregation

    K Number
    K112390
    Device Name
    MONICA AN24
    Date Cleared
    2012-07-13

    (330 days)

    Product Code
    Regulation Number
    884.2720
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    MONICA AN24

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Monica AN24 is an intrapartum maternal-fetal monitor that non-invasively measures and displays fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA). The AN24 acquires and displays the FHR & MHR tracing from abdominal surface electrodes that pick up the fetal ECG (fECG) and maternal ECG (mECG) signal. Using the same surface electrodes, the AN24 also acquires and displays the UA tracing from the uterine electromyography (EMG) signal. The AN24 is indicated for use on women who are at term (>36 completed weeks), in labor, with singleton pregnancies, using surface electrodes on the maternal abdomen.

    The AN24 maternal-fetal monitor is intended for use by healthcare professionals in a clinical setting.

    Device Description

    The Monica AN24™ is a small, battery-powered device for L&D surveillance of fetal well-being. The AN24™ is designed to passively monitor Fetal Heart Rate (FHR)), maternal heart rate (MHR) and Uterine Activity (UA) during pregnancy and can be used at any time from > 36 completed weeks gestation in laboring patients. The AN24™ is suitable for singleton pregnancies only.

    The Monica AN24 is a small, battery powered electrophysiological monitor (specifically fetal ECG, maternal ECG and uterine EMG). The electrical signals are passively monitored on three channels using five electrodes placed on the pregnant abdomen in specific locations. From these electrical signals the Fetal Heart Rate (FHR), maternal heart rate (MHR) and Uterine Activity (UA) are continuously extracted and displayed in the same standard format as the predicate device.

    AI/ML Overview

    Here's an analysis of the Monica AN24 device's acceptance criteria and study, based on the provided 510(k) summary:

    Monica AN24 Device Acceptance Criteria and Study Analysis

    The Monica AN24 is an intrapartum maternal-fetal monitor. This 510(k) summary focuses on demonstrating the substantial equivalence of the Monica AN24's Maternal Heart Rate (MHR) monitoring capability to a predicate SPO2 pulse oximeter (Philips M1191A). The FHR and UA monitoring capabilities had previously been cleared (K101801).


    1. Table of Acceptance Criteria and Reported Device Performance

    The study aimed to demonstrate non-inferiority of the Monica AN24's MHR monitoring compared to the predicate SPO2 pulse oximeter.

    Acceptance Criterion (Null Hypothesis of Inferiority, Alternative Hypothesis of Non-Inferiority)Reported Device Performance (Monica AN24 vs. Predicate SPO2)Outcome
    Reliability: Success Rate Ratio
    (Lower limit of CI > 0.8)Mean SR Ratio (AN24/SPO2): 1.16
    CI: 1.08 - 1.21Met
    Accuracy: RMS Error
    (Upper limit of 95% CI for RMS error
    Ask a Question

    Ask a specific question about this device

    K Number
    K101801
    Device Name
    MONICA AN24
    Manufacturer
    Date Cleared
    2011-02-03

    (220 days)

    Product Code
    Regulation Number
    884.2720
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Device Name :

    MONICA AN24

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Monica AN24 is an intrapartum maternal-fetal monitor that non-invasively measures and displays fetal heart rate (FHR) and uterine activity (UA). The AN24 acquires and displays the FHR tracing from abdominal surface electrodes that pick up the fetal ECG (fECG) signal. Using the same surface electrodes, the AN24 also acquires and displays the UA tracing from the uterine electromyography (EMG) signal. The AN24 is indicated for use on women who are at term (>36 completed weeks), in labor, with singleton pregnancies, using surface electrodes on the maternal abdomen.

    The AN24 maternal-fetal monitor is intended for use by healthcare professionals in a clinical setting.

    Device Description

    The Monica AN24™ is a small, battery-powered device for L&D surveillance of fetal well-being. The AN24™ is designed to passively monitor Fetal Heart Rate (FHR) from the fetal electrocardiogram (fECG) and Uterine Activity (UA) from the Electrohysterogram (EHG) during pregnancy and can be used at any time from > 36 completed weeks gestation in laboring patients. The AN24™ is suitable for singleton pregnancies only.

    The Monica AN24 is a small, battery powered electrophysiological monitor (specifically fetal ECG and uterine EMG). The electrical signals are passively monitored on three channels using five electrodes placed on the pregnant abdomen in specific locations. From these electrical signals the Fetal Heart Rate (FHR) and Uterine Activity (UA) are continuously extracted and displayed in the same standard format as the predicate device.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study details for the Monica AN24 device, based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria are not explicitly stated as distinct thresholds in the document, but rather implied by the non-inferiority comparison to the predicate device and the reported outcomes from the clinical study. The study aimed to demonstrate that the Monica AN24 is at least as accurate and reliable as the predicate device. Therefore, the "acceptance criteria" can be inferred as performance greater than or equal to the predicate device for each metric.

    MetricImplied Acceptance Criteria (relative to Predicate)Reported Monica AN24 PerformanceReported Predicate Performance (Philips 50XM)
    Fetal Heart Rate (FHR) Interpretability (PPA)≥ 72%85%72%
    FHR Accuracy (RMS Error)≤ 12 bpm5 bpm12 bpm
    Uterine Activity (UA) Interpretability (PPA)≥ 67%97%67%
    UA Sensitivity Accuracy (Sensitivity for Contractions)≥ 55%89%55%
    UA Timing Accuracy (Mean Timing Difference for Contractions)≤ 3.3 seconds lag2.5 seconds lag3.3 seconds lag

    2. Sample Sizes and Data Provenance

    • Test Set (Clinical Study):
      • Total Subjects Enrolled: 60 women.
      • Evaluable Data Subjects: 34 subjects.
      • FHR Study Subjects: 33 women.
      • UA Study Subjects: 30 women.
      • Data Provenance: The study was conducted at two clinical sites: QHC, New York, and Temple University, Philadelphia. This indicates prospective data collection in the USA.
      • Training Set Sample Size: Not explicitly stated. The document describes a "clinical equivalence trial" and a "subsequent Multi-Reader-Multi-Case (MRMC) study," which are generally used for validation/testing.

    3. Number of Experts and Qualifications for Ground Truth (Test Set)

    • Number of Experts: Four.
    • Qualifications of Experts: Board Certified Obstetricians. (Specific years of experience are not mentioned).

    4. Adjudication Method (Test Set)

    • Uterine Activity (UA): The uterine activity data was "independently reviewed in a Multi-Reader Study by four Board Certified Obstetricians who independently indicated on randomized trace segments." The results were "averaged" to establish the ground truth for UA. This aligns with a form of consensus-based adjudication, likely an average or 4/4 agreement model, though the exact decision rule isn't specified beyond "average of 4 board certified obstetricians."
    • Fetal Heart Rate (FHR): The ground truth for FHR was established directly by the "Direct fetal Scalp ECG (second Phillips Series 50XM device)," which served as the gold standard. No expert adjudication was mentioned for FHR.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    • Was an MRMC study done? Yes, a "Multi-Reader-Multi-Case (MRMC) study" was integral to the evaluation of Uterine Activity (UA).
    • Effect Size of Human Readers' Improvement with AI vs. without AI assistance: The document focuses on the performance of the device itself (Monica AN24 or predicate) compared to the gold standard, with human readers involved in establishing the ground truth for UA and in reviewing "False Positives." It does not describe a comparative effectiveness study where human readers interpret tracings with and without AI assistance to measure reader improvement. The MRMC study in this context refers to multiple readers evaluating the output of different devices (Monica AN24, TOCO, IUPC) to derive ground truth and compare device performance.

    6. Standalone (Algorithm Only) Performance Study

    • Yes, the study primarily assessed the standalone performance of the Monica AN24 device (algorithm only), comparing its output directly against established gold standards (fetal scalp ECG for FHR, IUPC for UA). The metrics (PPA, RMS error, sensitivity, timing accuracy) are all measures of the device's inherent performance.

    7. Type of Ground Truth Used

    • Fetal Heart Rate (FHR): Direct fetal Scalp ECG (from a second Philips Series 50XM device). This is a direct physiological measurement considered the gold standard.
    • Uterine Activity (UA): Intrauterine Pressure Catheter (IUPC) (from a Philips Series 50XM device), with expert consensus from four Board Certified Obstetricians used to interpret the tracings and mark contractions. This is a combination of direct physiological measurement and expert consensus/adjudication.

    8. Sample Size for the Training Set

    • The document does not explicitly state the sample size used for training the Monica AN24 device's algorithms. The described study is a clinical equivalence trial used for validation of the device's performance against a gold standard and a predicate, not for training.

    9. How Ground Truth for the Training Set was Established

    • The document does not provide information on how ground truth was established for the training set, as the focus is on the clinical validation study for regulatory submission.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1